A detailed history of Vantage Consulting Group Inc transactions in Catalent, Inc. stock. As of the latest transaction made, Vantage Consulting Group Inc holds 4,198 shares of CTLT stock, worth $254,860. This represents 0.39% of its overall portfolio holdings.

Number of Shares
4,198
Previous 4,207 0.21%
Holding current value
$254,860
Previous $237,000 0.42%
% of portfolio
0.39%
Previous 0.35%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$53.58 - $57.02 $482 - $513
-9 Reduced 0.21%
4,198 $236,000
Q1 2024

May 15, 2024

SELL
$42.56 - $59.82 $88,950 - $125,023
-2,090 Reduced 33.19%
4,207 $237,000
Q4 2023

Feb 14, 2024

BUY
$32.18 - $46.57 $48,656 - $70,413
1,512 Added 31.6%
6,297 $282,000
Q3 2023

Nov 14, 2023

SELL
$44.2 - $50.2 $50,785 - $57,679
-1,149 Reduced 19.36%
4,785 $217,000
Q2 2023

Aug 11, 2023

BUY
$31.86 - $67.26 $76,750 - $162,029
2,409 Added 68.34%
5,934 $257,000
Q1 2023

May 10, 2023

SELL
$45.44 - $74.26 $89,107 - $145,623
-1,961 Reduced 35.75%
3,525 $231,000
Q4 2022

Feb 13, 2023

BUY
$41.39 - $81.0 $227,065 - $444,366
5,486 New
5,486 $246,000
Q2 2022

Aug 09, 2022

SELL
$87.2 - $114.05 $11,859 - $15,510
-136 Reduced 5.69%
2,253 $242,000
Q1 2022

May 16, 2022

BUY
$94.19 - $124.49 $24,960 - $32,989
265 Added 12.48%
2,389 $265,000
Q4 2021

Feb 14, 2022

BUY
$119.57 - $139.07 $43,643 - $50,760
365 Added 20.75%
2,124 $272,000
Q3 2021

Nov 10, 2021

SELL
$109.17 - $142.35 $34,388 - $44,840
-315 Reduced 15.19%
1,759 $234,000
Q2 2021

Aug 11, 2021

BUY
$100.34 - $115.69 $208,105 - $239,941
2,074 New
2,074 $224,000
Q1 2021

May 14, 2021

SELL
$101.51 - $125.27 $175,510 - $216,591
-1,729 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$85.88 - $105.36 $148,486 - $182,167
1,729 New
1,729 $180,000

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $10.9B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Vantage Consulting Group Inc Portfolio

Follow Vantage Consulting Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vantage Consulting Group Inc with notifications on news.